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Human Lipoaspirate as Autologous Injectable Active Scaffold for 
One-Step Repair of Cartilage Defects
Michela Bosetti,* Alessia Borrone,† Antonia Follenzi,† Fanuel Messaggio,‡ 
Carlo Tremolada,§ and Mario Cannas†
*Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara, Italy
†Dipartimento di Scienze della Salute, Università del Piemonte Orientale, Novara, Italy
‡Diabetes Research Institute, University of Miami, Miami, FL, USA
§IMAGE Institute, Milan, Italy
Research on mesenchymal stem cells from adipose tissue shows promising results for cell-based therapy in 
cartilage lesions. In these studies, cells have been isolated, expanded, and differentiated in vitro before trans-
plantation into the damaged cartilage or onto materials used as scaffolds to deliver cells to the impaired area. 
The present study employed in vitro assays to investigate the potential of intra-articular injection of micro-
fragmented lipoaspirate as a one-step repair strategy; it aimed to determine whether adipose tissue can act 
as a scaffold for cells naturally present at their anatomical site. Cultured clusters of lipoaspirate showed a 
spontaneous outgrowth of cells with a mesenchymal phenotype and with multilineage differentiation poten-
tial. Transduction of lipoaspirate clusters by lentiviral vectors expressing GFP evidenced the propensity of 
the outgrown cells to repopulate fragments of damaged cartilage. On the basis of the results, which showed 
an induction of proliferation and ECM production of human primary chondrocytes, it was hypothesized that 
lipoaspirate may play a paracrine role. Moreover, the structure of a floating culture of lipoaspirate, treated for 
3 weeks with chondrogenic growth factors, changed: tissue with a high fat component was replaced by a tissue 
with a lower fat component and connective tissue rich in GAG and in collagen type I, increasing the mechani-
cal strength of the tissue. From these promising in vitro results, it may be speculated that an injectable autolo-
gous biologically active scaffold (lipoaspirate), employed intra-articularly, may 1) become a fibrous tissue that 
provides mechanical support for the load on the damaged cartilage; 2) induce host chondrocytes to proliferate 
and produce ECM; and 3) provide cells at the site of injury, which could regenerate or repair the damaged or 
missing cartilage.
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INTRODUCTION
The treatment of degenerative joints is becoming a 
very frequent necessity. Increased life expectancy and 
inappropriate medical treatments (e.g., removal of the 
meniscus) are leading to an increase in chondropathies 
and osteoarthritis, which also occur at a relatively young 
age. Chondrocytes are the parenchymal cells of carti-
lage and have limited regenerative capacity; thus, after 
traumatic injury, the cartilage undergoes degenerative 
changes, which may be irreversible (18). The more super-
ficial lesions tend to progress toward degeneration (29); 
those that penetrate the subchondral bone progress toward 
the formation of fibrocartilage tissue. This differs from 
normal hyaline cartilage in both biomechanical and bio-
chemical properties and frequently undergoes subsequent 
degeneration (30). Any cartilage lesion should therefore 
be considered as the beginning of a chronic degenerative 
disease with little chance of cure due to the poor regen-
erative capacity of this type of cell (7).
Modern treatments for damaged cartilage and for the 
prevention of osteoarthritis include the intra-articular 
administration of hyaluronan (15), treatment with platelet-
rich plasma (PRP) (3), bone marrow stimulation techniques 
(subchondral drilling, abrasion, microfracture) (24), osteo-
chondral grafting (mosaicplasty) (23), autologous chondro-
cyte implantation (ACI), and matrix-assisted autologous 
chondrocyte implantation (MACI) with autologous chon-
drocytes cultured on collagen membranes prior to reimplan-
tation (11). Chondrocyte-based therapy has demonstrated 
promising clinical results, but the procedure requires an 
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invasive protocol, in which autologous cartilage is har-
vested from the patient at a healthy anatomical site. This 
produces damage to the normal cartilage at that site lead-
ing to pathological changes. It is therefore evident that to 
avoid the disadvantages arising from the use of autologous 
chondrocytes, alternative cell sources must be investigated. 
Mesenchymal stem cells (MSCs) obtained from adult tis-
sues of different origins (umbilical cord blood, adipose 
tissue, bone marrow, synovial membranes, periosteum, 
and muscle) have recently been investigated and their 
chondrogenic potential assessed and compared (14,28,34). 
Bone marrow and adipose tissue are the most readily avail-
able sources of MSCs. Moreover, adipose tissue is readily 
available in large quantities and can be obtained through 
less invasive procedures; of the many cell types contained 
in adipose tissue, MSCs (ASCs) comprise up to 2%, 
whereas only 0.02% of cells in bone marrow are MSCs 
(BM-MSCs) (20). MSCs have shown promising results for 
cartilage repair (31); however, in the studies published to 
date, cells were isolated from the originating tissue, then 
expanded and differentiated in vitro, prior to transplanta-
tion into the damaged cartilage or seeding in materials used 
as scaffolds to deliver cells to the injured area. No optimal 
stimulation regimen has yet been proposed to differenti-
ate stem cells into chondrocytes prior to implantation; fur-
ther difficulty lies in the large number of processing steps 
(enzymatic digestion, cell expansion, and differentiation), 
which increases the translational barriers.
With the aim of avoiding excessive handling of stem 
cells and side effects derived from the scaffolds used for 
cell-based cartilage repair, this in vitro study investi-
gated whether the intra-articular injection of autologous 
lipoaspirate might be an alternative cell-based therapy in 
treating cartilage diseases and in preventing osteoarthri-
tis. Lipoaspirate is a natural scaffold rich in stem cells, 
which, when injected into the intra-articular space, might 
give rise to different biological responses. To determine 
whether lipoaspirate can lead to the outgrowth of cells 
to the damaged cartilage, thus repopulating and repair-
ing it, and whether lipoaspirate may have a paracrine 
effect on resident chondrocytes, we studied in vitro 
1) the ability of resident cells in lipoaspirate to grow 
out from adipose tissue, 2) the phenotype of these out-
growing cells, together with their differentiation poten-
tial and their capability of repopulating an organ culture 
of human cartilage, and 3) the effect of the lipoaspirate 
on the proliferation rate of human chondrocytes and on 
their production of cartilaginous matrix. Furthermore, 
with the aim of determining whether lipoaspirate clus-
ters might differentiate into a different tissue at the intra-
articular site, thus providing intra-articular mechanical 
reinforcement, the chondrogenic differentiation of cells 
not extracted from lipoaspirate, but simply at their own 
natural anatomical site, was examined.
MATERIALS AND METHODS
Materials
Lipoaspirates were obtained from five healthy female 
patients (age range 30–45) undergoing an elective lipo-
suction from a single anatomical site (abdominal sub-
cutaneous fat tissue) at the IMAGE Institute (Milan, 
Italy). The ethical committee of the University of Milan 
approved the design of the study. Exclusion criteria were 
body mass index (BMI) >30, diabetes, hypertension, and 
nicotine or alcoholic abuse. Written informed consent, 
specifying that residual material destined to be disposed 
of could be used for research, was signed by each par-
ticipant before the biological materials were removed, in 
agreement with Rec(2006)4 of the Committee of Ministers 
Council of Europe on research on biological materials of 
human origin. After a preliminary infiltration of 400 ml of 
saline solution, with adrenaline 2 mg/ml (S.A.L.F. Spa., 
Bergamo, Italy) as a vasoconstrictor and lidocaine 0.02% 
(AstraZeneca, Luton, UK) as an anesthetic, the aspiration 
was performed using a 10-cc syringe with a Luer-Lok® tip 
(BD Medical, VWR Int., Milano, Italy) connected to a dis-
posable 19-cm blunt cannula (3 mm OD), with five oval 
holes (1 × 2 mm). From each of five patients, 210 ml of 
lipoaspirate was obtained and processed as follows, giving 
four batches of lipoaspirate: 10 ml was washed with 25 ml 
of phosphate-buffered saline (PBS; Sigma-Aldrich, Milan, 
Italy) on a 250-mm Nitex filter (Dutscher Scientific, Essex, 
UK) and used as control (CTR); 50 ml was centrifuged 
for 3 min at 1,500 × g (22) and 10 ml used as Coleman 
(Col); 50 ml was processed with a commercial device 
(PureGraft®; Cytori Therapeutics, San Diego, CA, USA) 
according to the manufacturer’s instructions (25) and 10 ml 
used (PurGr); 100 ml was processed with a commercial 
device (Lipogems®; Lipogems Int. S.p.A., Milano, Italy) 
that washes and micronizes lipoaspirate (4) following the 
manufacturer’s instructions, and 10 ml was used (LipoG).
Chondrogenic Organ Culture Model
Each batch (500 ml) of lipoaspirate was cultured as 
free-floating aggregates in a conical polypropylene cen-
trifuge tube (EuroClone, Milan, Italy) in 4 ml of chon-
drogenic medium containing 1 ml Dulbecco’s modified 
Eagle medium (DMEM-high glucose; Sigma-Aldrich), 
ascorbate-2-phosphate (100 mM; Sigma-Aldrich), dexa-
methasone (10−7 M; Sigma-Aldrich), and 1% insulin– 
transferrin–selenite (ITS+1 media supplement; Sigma-
Aldrich) for 3 weeks at 37°C in a humidified atmosphere 
containing 95% air and 5% CO2. The tubes were gently 
shaken daily to allow the culture media to cover the sam-
ple, which otherwise tended to float. Half of the culture 
medium was changed twice a week with the addition 
of fibroblast growth factor 2 (FGF2) and transforming 
growth factor-b2 (TGF-b2) found in previous research 
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to be chondrogenic on bone marrow stem cells (6). 
Replicate aggregates from each batch of lipoaspirate were 
processed for the following determinations: histological 
and immunohistological evaluation, mechanical evalua-
tions, biochemical studies, RNA extraction, and RT-PCR 
analysis. Before processing, digital images were taken of 
each lipoaspirate organ culture using a digital camera, on 
samples treated or not for 3 weeks with the chGF.
Mechanical Evaluations
The compression properties of untreated and chGF-
treated lipoaspirates were tested using an Electro Force 
BioDynamic Test Instrument (Bose; TA Instruments, 
Eden Prairie, MN, USA). Samples of 2 ± 0.5 mm3 were 
positioned inside the instrument’s bioreactor chamber 
between two pistons. Tests were performed with a constant 
crosshead speed of 0.05 mm/s. The instrument showed 
the real-time displacement of the piston and the force act-
ing on the sample, producing a force/displacement curve. 
Compressive strength and Young modulus were then cal-
culated, using the surface area of the sample, initial length 
of the sample, compressed length, and force at breaking 
point. All samples were tested in triplicate, and data are 
presented as mean ± standard deviation (SD).
Histology and Immunohistochemistry
After 21 days of culture, neoformed tissues were 
rinsed in PBS and fixed overnight in 10% buffered for-
malin (Diapath S.r.l., Martinengo, Italy) at 4°C. The 
fixed tissues were dehydrated by treatment with alcohol, 
embedded in paraffin, and sectioned to a thickness of 
7 mm. For histological evaluation, sections were depar-
affinized using xylene, rehydrated, and stained with 
hematoxylin and eosin (H&E; Sigma-Aldrich) or tolui-
dine blue (Sigma-Aldrich) to detect proteoglycan or with 
Sirius red F3BA (Chroma, Stuttgart, Germany) to detect 
collagen. Alternate sections were used for immunohis-
tochemistry to detect vessels: rehydrated sections were 
treated with 0.5% H2O2 (Sigma-Aldrich) to inactivate 
endogenous peroxidases, incubated in 1 mg/ml pepsin 
(Sigma-Aldrich) in 0.5 M acetic acid (Sigma-Aldrich) 
for 2 h at 37°C, blocked with 1.5% goat serum (Vector 
Laboratories, Burlingame, CA, USA) in PBS for 1 h at 
room temperature, and incubated for 1 h at room temper-
ature with anti-Von Willebrand factor 25 mg/ml (Dako, 
Glostrup, Denmark) and FITC-conjugated secondary 
antibody 10 mg/ml (Vector Laboratories).
Glycosaminoglycan and Collagen Quantification
Weighed tissue (2 mg) was taken after 21 days of cul-
ture, washed with PBS, and digested with 200 ml papain 
(1 mg/ml in 50 mM NaH2PO4, pH 6.5, containing 2 mM 
N-acetyl cysteine and 2 mM EDTA; all from Sigma-
Aldrich) for 16 h at 65°C. Glycosaminoglycans were 
quantified by reaction with 1.9-dimethylmethylene blue 
(16 mg/ml DMMB; Sigma-Aldrich) (12) using chondroitin 
sulfate (Sigma-Aldrich) as a standard. Measurements were 
made with a microplate reader (BS 1000 Spectracount; 
Packard BioScience Company, Meriden, CT, USA) at 
a wavelength of 530 nm. The results are reported as 
mean ± SD (n = 3) mg sGAG content/mg of the tissue and 
as percent increase versus untreated sample (21 days of 
culture in basal medium).
Collagen was quantified according to Tullberg-Renert 
and Jundt (32). Briefly, 2 mg of tissue was extracted 
overnight at 4°C in 0.5 ml of acetic acid 0.2%, air dried, 
and stained with 1 ml of Sirius red dye (Sigma-Aldrich) 
reagent (1 mg/ml in saturated aqueous picric acid; Sigma-
Aldrich) for 1 h. The dye solution was then removed, and 
the tissue was washed with 0.01 N hydrochloric acid 
(Sigma-Aldrich) to remove all nonbound dye; the stained 
material was dissolved in 0.2–0.3 ml 0.1 N of sodium 
hydroxide for 30 min at room temperature. The optical 
density (OD) was measured with a Bio-Rad microplate 
reader 3550 (Bio-Rad, Milan, Italy) at 550 nm against 
0.1 N of sodium hydroxide as blank. The results are 
reported as means ± SD (n = 3) mg collagen/ml and as 
percent increase versus the untreated sample (21 days of 
culture in basal medium).
Real-Time PCR
Total cellular RNA was extracted using a Qiagen 
QIAsshredder kit (Qiagen, Dusseldorf, Germany) and 
quantified using a RiboGreen RNA quantification assay 
(Molecular Probes, Invitrogen, Milan, Italy). Then 200 
ng was reverse transcribed (RT) using a High-Capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, 
CA, USA). The RT thermal profile was 25°C for 10 min, 
37°C for 120 min, 85°C for 5 min, and kept at 4°C. 
Primers and probe were provided by TaqMan gene 
expression assay kit (Applied Biosystems) and were 
added to the reaction mixture according to the manufac-
turer’s directions: SOX-9 (Hs01001343_g1), COL2A1 
(Hs00264051_m1), COL1A1 (Hs00164004_m1), and 
GADPH (Hs02758991_g1). Amplification reactions 
were performed with SSOFast Probes Supermix with 
ROX (Bio-Rad). mRNA levels were measured by real-
time RT-PCR based on TaqMan methodology, using 
CFX96 Real-Time System C 1000 Thermal Cycler (Bio-
Rad). Real-time data analysis was run with Bio-Rad CFX 
Manager 2.1 software. Target gene expression was nor-
malized to GADPH mRNA expression. Relative differ-
ential gene expression was calculated (27).
Isolation and Culture of Human Chondrocytes (hChs)
Normal human articular cartilage was obtained from 
the femoral or radial heads of three male subjects with dis-
placed fractures. The mean age of the group was 33 years 
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(range: 20–41). Written consent was signed by each par-
ticipant before biological materials were removed accord-
ing to Rec (2006)4 of the Committee of Ministers Council 
of Europe and used after local ethics committee approval. 
Immediately after surgery was performed at the traumatol-
ogy division of the Major Hospital of Novara, healthy car-
tilage was taken under sterile conditions, washed with PBS 
supplemented with 50 U/ml penicillin, 50 mg/ml streptomy-
cin, and 250 ng/ml Fungizone (PSF; all reagents from Sigma-
Aldrich) and cut into pieces of approximately 2 × 2 mm, 
before enzymatic digestion, as follows and according to 
Archer et al. (1). Pieces were placed for 30 min at 37°C, 
5% CO2 in DMEM/F12 (EuroClone) containing trypsin 
(0.25% w/v; Sigma-Aldrich) and PSF (100–120 rpm 
shaking); the supernatant was discarded, and the cartilage 
fragments were further digested in DMEM/F12 with PSF 
containing 0.8 mg/ml collagenase II (Sigma-Aldrich) for 
4 h at 37°C, 5% CO2 (100–120 rpm shaking). The digested 
tissue was then allowed to settle, and the supernatant con-
taining cells was centrifuged at 1,500 × g for 5 min. The 
cell pellet was washed with PBS-PSF and resuspended 
in growth medium: DMEM/F12 supplemented with PSF, 
glutamine 200 mM (EuroClone), ascorbic acid 50 mg/ml 
(Sigma-Aldrich), FBS 2% (EuroClone), 1 ng/ml TGF-b 
(Sigma-Aldrich), 1 ng/ml FGF2 (Sigma-Aldrich), 10 mg/
ml ITS+1 (Sigma-Aldrich), seeded in monolayer in culture 
plates at low density (4,000 cell/cm2) and incubated in a 
CO2 incubator at 5% CO2, 37°C.
Effect of Lipoaspirate on hCh Proliferation 
and Matrix Production
Chondrocytes were used for the experiments within 
the third expansion treatment. They were plated at a 
density of 103 cells/well in a 96-multiwell plate, and 
hChs were cultured in basal culture medium (DMEM/
F12 supplemented with antibiotics, glutamine ascorbic 
acid, 2% FBS, 1 ng/ml TGF-b, 1 ng/ml FGF2, 10 mg/
ml ITS+1 as described for hChs culture and abbreviated 
CTR) and compared to cells cultured in lipoconditioned 
culture medium made up of basal culture medium supple-
mented with 15% of lipoaspirate culture medium that was 
obtained as follows. Lipoaspirate (1 ml) corresponding 
to 850 ± 20 mg of tissue was cultured in 10 ml of basal 
medium in a CO2 incubator at 5% CO2, 37°C for 4 days; 
upon this treatment, extracellular proteins were released 
into the medium. Chondrocytes were cultured in basal 
or in lipoconditioned culture medium for 1, 3, 6, and 12 
days; after each incubation time, cell proliferation and 
cartilaginous matrix production were assayed.
For the proliferation assay, an ATP quantification Kit 
(ViaLight, Cambrex Profarmaco, Milan, Italy) was used 
following the manufacturer’s protocol. Briefly, cells 
were lysed with cell lysis reagent, supplied with the kit, 
and treated with ATP monitoring reagent, which utilizes 
luciferase and was supplied with the kit. The light pro-
duced was measured by a luminometer (Victorä X4; 
PerkinElmer, Milan, Italy) and expressed as relative 
luminescence units (RLUs) (9). For the cartilaginous 
matrix production assay 0.1 ml of each standard or cul-
ture medium to be tested was added to 0.1 ml of DMMB 
dye in 96-microplate wells; they were read in a micoplate 
reader at A525.
Cell Outgrowth From Lipoaspirate
The outgrowth of cells from Col and LipoG clusters 
was studied by quantifying, on the bottom of the well, the 
number of cells that had grown out from 50 mg of tissue/
well, when the lipoaspirate was cultured in floating condi-
tions in a 24-multiwell dish, from time 0 to 18 days. The 
outgrowth study was done also in a 3D matrix, as fol-
lows: To 50 ml of collagen solution, obtained from rat tail 
tendon (10), a cluster of lipoaspirate was added, prior to 
gel formation, which was achieved within 1 h of incuba-
tion at 37°C in culture medium (DMEM with 10% FBS, 
100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM 
l-glutamine; all from Sigma-Aldrich). The kinetics of cell 
outgrowth and the number of cells/mg tissue were evalu-
ated by quantifying 4¢,6-diamidino-2-phenylindole (DAPI; 
Sigma-Aldrich)-positive cells. Briefly, 3D collagen gels 
were fixed in formalin 4% for 1 h at room temperature and 
stained for 10 min with 300 nM DAPI (Molecular Probes), 
before counting nuclear positivity by fluorescence micros-
copy (Leica Microsystems, Milan, Italy).
Cell Phenotype Characterization With Flow 
Cytometry Analysis
To determine whether the mechanical and enzymatic 
treatments, normally used to isolate stem cells from adi-
pose tissue for regenerative medicine applications, may 
be avoided, the phenotype of cells obtained by outgrowth 
from the clusters was compared to that of cells obtained 
as follows. After digestion of lipoaspirate with type I col-
lagenase 1 mg/ml in PBS (Sigma-Aldrich) at 37°C for 
30–60 min, the stromal-vascular fraction (SVF) contain-
ing ASCs was obtained through centrifugation for 10 min 
at 450 × g. Cell pellets were resuspended in red blood 
cell lysis buffer (2.06 g/L Tris base, pH 7.2, and 7.49 g/L 
NH4Cl; Sigma-Aldrich) and incubated at room tempera-
ture for 10 min, to remove any remaining erythrocytes. 
Pellets were collected and filtered sequentially through 
100- and 40-mm cell strainers (VWR Int.) to remove undi-
gested tissue. The pellets were then washed and the cells 
resuspended in DMEM/Ham’s F12 medium (v/v 1:1) sup-
plemented with 10% FBS, 100 U/ml penicillin, 100 μg/
ml streptomycin, and 2 mM l-glutamine, and plated in a 
75-cm2 tissue culture flask coated with collagen (Thermo 
Scientific, Waltham, MA, USA). ASCs were self-selected 
out of the SVF, based on their adherent phenotype, during 
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subsequent tissue culture passages, after which they were 
maintained in a humidified atmosphere with 5% CO2 in 
an incubator at 37°C. Cells were incubated with 1 mg/106 
cells of fluorescent antibodies for 40 min at 4°C in the 
dark. The antibodies used were anti-CD146 (10 μg/ml), 
anti-CD105 (10 μg/ml), anti-CD90 (10 μg/ml), anti-CD73 
(5 μg/ml), anti-CD45 (5 μg/ml), anti-CD44 (3.5 μg/ml), 
anti-CD34 (7.5 μg/ml), and anti-CD31 (2.5 μg/ml) (all 
from BioLegend, San Diego, CA, USA). After washing, 
cells were analyzed on a flow cytometer (FACSAria; BD 
Biosciences, San Jose, CA, USA) by collecting 10,000 
events, and the data were analyzed using the FACSDiva 
Software (BD Biosciences).
Cell Differentiation Capacity
To confirm the mesenchymal activity of those cells that 
grew out naturally from the lipoaspirate clusters, while under 
culture conditions, their in vitro differentiation capacity was 
studied according to Noël et al. (26). Briefly, 10 × 103 cells/
cm2 were cultured in DMEM-low glucose supplemented 
with 10% FBS, 0.5 mM isobutyl-methyl xanthine (IBMX; 
Sigma-Aldrich), 200 μM indomethacin, 1 μM dexametha-
sone, and 10 μg/ml insulin (all from Sigma-Aldrich); after 
2 weeks they were stained with fresh Oil red O solution 
(Sigma-Aldrich) for adipogenesis. After 3 weeks of cul-
ture in DMEM-low glucose supplemented with 10% FBS, 
10 mM b-glycerophosphate, 0.2 mM ascorbic acid, and 
10 nM dexamethasone (all from Sigma-Aldrich), for osteo-
genic differentiation, cells were stained with calcein solu-
tion (Sigma-Aldrich) to evidence mineralization (16) and 
with 5-bromo-4-chloro-3-indolyl phosphate (BCIP; Sigma-
Aldrich) to evidence alkaline phosphatase activity (8). To 
demonstrate chondrogenic differentiation, pellets of 5 × 105 
cells were cultured for 3 weeks in chondrogenic medium 
(Lonza, Cologne, Germany), formalin-fixed, embedded in 
paraffin, and immunostained for type II collagen by incuba-
tion with rabbit polyclonal anti-collagen type II primary anti-
body 1 mg/ml (Biogenesis, Oxford, UK) and with secondary 
antibody conjugated to peroxidase (Vector Laboratories).
Transduction and Examination of Lenti-GFP 
Lipoaspirates
High-titer VSV-pseudotyped lentiviral vectors (LV) 
were produced in human embryonic kidney 293T cells 
(ATCC® CRL-3216Ô) by transient transfection with the 
lentiviral transfer vector construct pCCLsimPPT.PGK.
GFP.WPRE (Lenti-GFP) and purified by ultracentrifu-
gation, as described by Follenzi et al. (13). Expression 
titers for green fluorescent protein (GFP)-expressing 
vectors were determined on 293T cells by fluorescence-
activated cell sorting (FACS) analysis (FACSCalibur; BD 
Biosciences) and was between 5 × 109 and 1010 transduc-
ing units (TU)/ml. Clusters of lipoaspirate were trans-
duced by Lenti-GFP into serum-free DMEM for 24 h at 
37°C at several concentrations of LV particles (108–106 
TU/ml), and the most efficient concentration was selected 
after 48 h by scoring GFP-positive cells using fluores-
cence microscopy. The transduction efficiency was deter-
mined by counting GFP-positive and -negative cells in at 
least 10 representative high-power fields against DAPI 
(D-1306; Molecular Probes).
Evaluation of the Repair of Damaged Cartilage
GFP-LipoG clusters were cocultured with an organ 
culture of healthy or mechanically damaged cartilage, 
obtained from the head of the femur of one of the three 
fracture cases, and cultured in a 24-well plate in DMEM/
F12 supplemented with PSF, 200 mM glutamine, 50 mg/
ml ascorbic acid, FBS 2%, 1 ng/ml TGF-b, 1 ng/ml FGF2, 
and 10 mg/ml ITS+1. At 1, 3, 6, 12, and 24 days after the 
beginning of the culture, fluorescence microscopy was 
used to detect whether GFP-positive cells had migrated 
out from the lipoaspirate, to populate the cultured car-
tilage. To determine whether cells originating from the 
lipoaspirate (GFP-positive cells), which had repopulated 
the damaged cartilage, had differentiated into chondro-
cytes, SOX-9-Texas red (Santa Cruz Biotechnology, 
Heidelberg, Germany) immunostaining was applied. The 
repopulated cartilage was formalin fixed, and after 1 h 
of incubation in 5% goat serum and 0.2% Triton X-100 
(Sigma-Aldrich) in PBS it was incubated for 1 h at 
room temperature with a rabbit polyclonal antibody for 
SOX-9 2 mg/ml (Santa Cruz Biotechnology, Heidelberg, 
Germany) and a Texas red-conjugated secondary anti-
body 10 mg/ml (Vector Laboratories).
Statistical Analysis
The data were analyzed statistically using the SPSS 
for Windows software package (Statistical Package for 
Social Science; IBM, Armonk, NY, USA). Multiple com-
parisons of data were performed using one-way analy-
sis of variance (ANOVA), and Bonferroni post hoc tests 
were applied to evaluate differences in mechanical prop-
erties, biochemical results, real-time PCR, and FACS. 
The value of p £ 0.05 level was considered to reflect sta-
tistical significance.
RESULTS
Chondrogenicity of Lipoaspirate
Morphological, mechanical, biochemical, and molecu-
lar characterization showed that treatment of the lipoaspi-
rate organ culture with the combined chondrogenic growth 
factors induced the formation of a tissue completely dif-
ferent from the starting material and from that treated for 3 
weeks in basal medium. Comparing the four lipoaspirates 
obtained with the four techniques described above, the 
washed lipoaspirate and that obtained with Col technol-
ogy showed similar behavior, while that obtained with the 
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LipoG technique produced the most significant changes in 
cellular organization, in mechanical properties of the newly 
formed tissue and also in its microscopic and molecular 
aspects. From the macroscopic image (Fig. 1A, B) it can 
be seen that the structure of all lipoaspirates changed after 
3 weeks of treatment with chondrogenic factors; the com-
pactness of the tissue had increased in all cases. However, 
the Col and PurGr lipoaspirates started from a tissue with a 
more compact texture than that of the LipoG batch; before 
treatment, the latter was characterized by individual iso-
lated micronized fat globules of 0.4 ± 0.1 mm2, whereas 
lipoaspirate, Col, and PurGr batches contained clusters 
of 1.8 ± 0.9 mm2. The newly formed tissues also showed 
statistically relevant differences in mechanical properties, 
measured under compression, using a Bose Electoforce 
instrument. The aggregation of the starting tissue was 
particularly evident in the case of the LipoG, which gen-
erated a compact structure, with about 270% increase 
compared to the starting value in both tensile strength 
(Fig. 1C) and Young modulus (Fig. 1D). Figure 1C and D 
shows samples before the 3 weeks of culture in the chon-
drogenic model and samples after the 3 weeks of culture 
in the chondrogenic model.
The histological and immunohistological analysis also 
showed considerable tissue modification (Fig. 2) with a 
reduction of the fatty component in favor of a connec-
tive tissue rich in GAGs (Fig. 2B), in collagen (Fig. 2C), 
and with a reduced presence of blood vessels (Fig. 2D). 
Comparing the histology of the lipoaspirates obtained 
with the four techniques tested, the LipoG batch (Fig. 2, 
panel 4) underwent the most significant changes in cellu-
lar organization, with only a few areas of adipose tissue, 
the remainder being almost completely replaced by col-
lagen and GAGs. These data were confirmed by the bio-
chemical quantifications, shown in Figure 3A for GAG 
and Figure 3B for collagen.
Since the PurGr batch of lipoaspirate gave the poor-
est performance in the preliminary experiments for the 
remainder of the study only the CTR, Col, and LipoG 
batches were employed. Real-time PCR showed that, 
before treatment, all three lipoaspirates expressed simi-
larly low levels of collagen type I, whereas none expressed 
mRNA for collagen type II, nor for SOX-9, at 40 cycles 
of PCR reaction. After 3 weeks of treatment in chondro-
genic culture medium, the mRNA of lipoaspirate clusters 
was altered in a similar direction, with an increase in gene 
expression of collagen type I, and a small increase in gene 
expression of SOX-9 (Fig. 3C). The increase in SOX-9 
gene expression was particularly evident in the LipoG 
batch. No collagen type II was detected.
Effect of Lipoaspirate on Chondrocytes
Culture medium from both Col and LipoG lipoaspirates 
was found to induce chondrocyte proliferation and ECM 
production to the same extent. As shown in Figure 4A, 
already 3 days after the addition of 15% lipoaspirate cul-
ture medium, a statistically significant increase in ATP 
levels occurred in both cases compared to the CTR. This 
increase was more evident at longer incubation times, 
reaching a plateau at 18 days of culture, with 80% more 
ATP in chondrocytes treated with 15% culture medium 
of the lipoaspirate and LipoG compared to CTR that 
were chondrocytes treated for the same period of time 
with 15% of the same culture medium used for lipoaspi-
rate culture. Moreover, as shown in Figure 4B, culture 
medium from the Col and LipoG batches activated ECM 
synthesis of chondrocytes, as shown by increased levels 
of GAGs.
Cell Outgrowth From Lipoaspirates: 
Quantification,Phenotype, Differentiation  
Capacity, and Cartilage Repopulation
The next stage of the research showed that the LipoG 
batch of lipoaspirate, when transferred into tissue culture, 
without any processing began to leave cells out from the 
tissue clusters after 2–3 days. Cells attached to the plastic 
of the tissue culture wells and reached 70–80% conflu-
ence in 7–12 days. Figure 5 shows representative images 
of cells grown out from the clusters: Figure 5A shows 
cells at the bottom of the plastic wells that had grown 
out from the clusters when cultured in floating condi-
tions, and Figure 5B shows cell outgrowth in the 3D col-
lagen culture model. Both lipoaspirates (Col and LipoG) 
showed good cell outgrowth from the clusters; the only 
difference was that, from the LipoG batch, outgrowth 
was faster than from the Col batch; further from the same 
weight of lipoaspirate, the number of cells from LipoG 
was higher than that from the Col batch. Of the two cul-
ture models studied, cell outgrowth was faster in the 3D 
collagen matrix than it was from the floating culture. Cell 
outgrowth was already visible within 2 days from time 
0 in the 3D culture model, whereas no cells were visible 
before 4–5 days in the floating culture.
FACS analyses (Fig. 5G) showed that cells obtained by 
outgrowth from the clusters expressed typical mesenchy-
mal markers (CD90, CD73, CD105, and CD44) at high 
percentages, close to 100%, and also CD146+ cell index 
of pericyte population (Fig. 5, bar graph). No statistically 
significant difference was found versus cells obtained 
by enzymatic digestion of the lipoaspirate. Furthermore, 
cells outgrown from the lipoaspirates were found to have 
the developmental potential of hMSCs (Fig. 5C–F). 
Adipogenic differentiation showed a progressive loss of 
the fibroblastoid-like shape and the production of cyto-
plasm lipid vacuoles (Fig. 5C). Osteogenic differentiation 
was revealed at the first week of induction by morpholog-
ical changes (from fibroblastoid-like to trapezoidal cells) 
and, at the end of the induction period, by the formation 
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of mineralized matrix (Fig. 5D) and of ALP-positive cells 
(Fig. 5E). Chondrogenic induction revealed abundant 
extracellular matrix positive to human type II collagen 
antibody (Fig. 5F).
LVs were used to transduce cultured clusters of lipoaspi-
rate. Transduction was visualized by GFP expression, and 
a very high transduction efficiency was demonstrated as 
shown by direct fluorescence (Fig. 6A). Transduction was 
not limited to the surface of the clusters, but was also evi-
dent in the inner part. Cell counts, performed with nuclear 
counterstaining, revealed that a mean of 62 ± 4% of cells 
of the cluster were GFP positive, and no cell loss was 
detected (p = 0.94 for comparison with control lipoaspi-
rates, n = 3). Moreover, 49 ± 20% of cells outgrown from 
the lipoaspirate clusters were GFP positive.
When GFP-transduced clusters were placed in an 
organ culture of healthy or mechanically damaged carti-
lage, it was found that, within a few days, positive cells 
grew out from the clusters; moreover, they only repopu-
lated the damaged cartilage (Fig. 6C) and not its healthy 
counterpart (Fig. 6B). Among GFP-positive cells, only 
10% showed SOX-9 colocalization, indicating that, in 
the organ culture model used, only 10% of cells outgrow-
ing from the lipoaspirate differentiated into chondrocytes 
(Fig. 6D).
DISCUSSION
The use of ASCs in regenerative medicine is a rapidly 
growing area of research. There is some in vitro evidence 
of success using these cells in osteochondral defect repair 
(17), and they have also recently been used successfully 
as a therapeutic tool in treating OA (5). ASCs have been 
available commercially for veterinary use since 2003, 
although little has been published documenting their 
clinical efficacy; such reports might minimize the gap 
between human and veterinary markets, accelerating the 
Figure 2. Histological and histochemical results. (A) Hematoxylin and eosin, (B) toluidine blue, (C) Sirius red, (D) Von Willebrand. 
CTR lipoaspirate before chondrogenic treatment (1), Col (2), PurGr (3), and LipoG (4) batches after 3 weeks of culture with chondro-
genic factors.
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introduction of stem cell-based cartilage repair for human 
diseases. Beneficial effects of ASCs have been reported 
in treating OA in some experimental animal models 
(19,33). However, these studies used a tissue-engineering 
approach, and a wide variety of biodegradable scaffolds 
were used to assist chondrogenic differentiation.
To our knowledge, use of an autologous biological tis-
sue, naturally rich in stem cells, implanted in a different 
anatomical site from where it was harvested (i.e., autolo-
gous transplantation of subcutaneous fat to intra-articular 
sites) has not been previously attempted. The present 
study has shown that it is possible to avoid stem cell 
isolation, expansion, and differentiation for several days 
in vitro, before autologous implantation with scaffold 
or scaffold-free approaches. We have demonstrated that 
microfragmented lipoaspirate clusters give rise to sponta-
neous cell outgrowth both when cultured in floating con-
ditions and in the 3D collagen matrix. Although adipose 
tissue contains adipose-derived stem cells, fibroblasts, 
endothelial cells, hematogenous cells, pericytes, adipo-
cytes, and preadipocytes, it was found that cells obtained 
naturally exhibit a mesenchymal phenotype with stem 
cell surface expression markers similar to those obtained 
through enzymatic extraction; they also have the capacity 
for multilineage differentiation, showing the classical 
commitment to osteogenic, chondrogenic, and adipogenic 
lineages. These data show that micronized lipoaspirate, 
acting as a natural scaffold for mesenchymal cells that are 
simply trapped in the stromal vascular portion, may be 
considered a source of autologous multipotent undiffer-
entiated cells. Since it requires no processing steps before 
use, the risk of infection or that of retaining enzymatic 
residues from tissue digestion during cell isolation can be 
avoided. This also reduces costs associated with a long 
period of cell expansion and differentiation (12–21 days) 
with residual of growth supplements, as well as the side 
effects associated with the natural or synthetic scaffolds 
used for cell-based cartilage repair. Despite these prom-
ising results, however, the physiological role of native 
adipose-derived stromal/stem cells in vivo is not fully 
understood, and more histological studies must be per-
formed before it may be deemed safe for clinical use. It 
will be necessary to identify in situ the expression of a 
wide range of markers; these may well include more than 
those studied to analyze culture-expanded preparations 
(2). The use of GFP-transduced lipoaspirates demon-
strated, in vitro, that cells outgrown from lipoaspirate can 
repopulate an organ culture of damaged cartilage. It may 
Figure 3. Biochemical quantification of GAG expressed as mg GAG per mg tissue (top left) and of total collagen expressed as 
absolute value in μg/ml (top right). Expression of chondrocytic markers in lipoaspirate tissue extracts normalized with GAPDH and 
reported as relative differential gene expression (bottom). For each sample, the reported values are from samples before (first column) 
and after (second column) chondrogenic treatment (21 days of culture in chGF-enriched chondrogenic medium). *p < 0.05 compared 
to the sample before chondrogenic treatment. The results are given as means ± SD (n = 3).
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therefore be hypothesized that, when intra-articular injec-
tion of human lipoaspirate enters clinical trials, it will give 
rise to cells having mesenchymal potential to repopulate 
the lesion. Moreover, there appears to be a possibility that 
native stem-like cells arising from lipoaspirate may have 
a better physiological phenotype and higher regenerative 
potential than cells obtained with the isolation technique 
and culture conditions generally used for ASC prepara-
tion prior to transplantation.
In addition to these data, the finding that lipoaspirate 
culture medium induced human primary chondrocyte pro-
liferation and ECM synthesis reinforces the promise of 
such preparations, comprising micronized fat, becoming 
a therapeutic tool for cartilage regeneration. The paracrine 
and endocrine secretions of adipose tissue have recently 
been described (19); fat might not be considered only as 
an energy storage tissue, but rather as an active tissue 
involved in the metabolism (21), in immunomodulatory 
Figure 4. Proliferation (A) and GAG production (B) of human primary chondrocytes cultured with 15% of culture medium from 
lipoaspirates. Results in (A) are expressed as mean ± SD relative to control cells (n = 3); results in (B) are reported as mean ± SD (n = 3) 
in μg/ml of sulfated glycosaminoglycans quantified in culture medium of chondrocytes cultured for 2 days and 8 days in basal medium 
(CTR) and in culture media supplemented with 15% medium from lipoaspirates (Col and LipoG). *p < 0.05 compared to CTR.
FACING PAGE
Figure 5. Cell outgrowth from clusters. Representative images at phase contrast microscopy of cells outgrown from clusters in 
the monolayer culture model (A) and in the 3D collagen matrix (B). (C–F) Representative microscopic images of four separate 
experiments of the multilineage differentiation capacity of the cells outgrowing from lipoaspirate. Adipogenic differentiation (C) was 
revealed by Oil red O staining for neutral lipids. Osteogenic differentiation was evidenced by the formation of mineralized matrix as 
shown in green by calcein staining (D) and ALP activity (E). Chondrogenic differentiation was revealed by immunohistochemical stain 
for collagen II (F). The bar graph (G) shows the immunophenotyping flow cytometry analysis of cells expanded from the enzymati-
cally digested lipoaspirate, and of cells outgrowing from cultured lipoaspirate. Data are expressed as means ± SD (n = 3) of the percent 
of positive cells for the indicated markers.
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activities, and in providing an extensive perivascular res-
ervoir of multipotent, undifferentiated cell populations, 
involved in homeostasis and regeneration. As a large 
microvascular bed, fat appears to provide an ideal pool 
of undifferentiated cells in close proximity to perivas-
cular access routes for the mobilization and relocation 
demands of injured or diseased structures. It is character-
ized by different cell types (including adipocytes, preadi-
pocytes, vascular cells, fibroblasts, pericytes, stem cells, 
and immune cells) that, by secreting a range of cytokines, 
growth factors, chemokines, and adipokines, might inter-
act with the resident cells of damaged tissue, inducing 
repair and regeneration. As for ASC preparations, which 
are already in clinical trials, many questions remain to be 
clarified concerning lipoaspirate differentiation potential 
in vivo, and the mechanisms involved in repair or regen-
eration (paracrine effects, differentiation, immunomodu-
lation), together with any donor-specific variability in 
cell quality and activity.
In an attempt to determine the fate of lipoaspirate when 
injected into a joint, it was induced to differentiate in 
vitro to form cartilage, as has generally been done using 
MSCs in a 3D culture model (6). Micronized fat (LipoG) 
responds better to differentiating stimuli than did the other 
batches, which contained clusters of larger size; this may 
be because the more micronized clusters have a greater 
surface area in contact with the culture medium containing 
chGF, giving the cells a greater response capacity. Based 
on these findings, it might be hypothesized that, when 
injected intra-articularly, lipoaspirate might become a 
fibrous tissue, having favorable mechanical, morphologi-
cal, biochemical, and molecular characteristics for its use 
at intra-articular sites. At in vitro examination, an abnor-
mal change in the nature of the adipose tissue was seen 
to have occurred, with residual fat globules surrounded 
by thick fibrous tissue rich in collagen and GAG that was 
reminiscent of metaplasia. Although the newly formed 
tissue was not hyaline cartilage, as demonstrated by the 
lack of expression of type II collagen, it showed histolog-
ical features and mechanical properties that in the joints, 
where the cartilage is damaged, would undoubtedly be 
superior to the classic viscosupplements used to alleviate 
the load acting on damaged cartilage. The fibrous intra-
articular sleeve produced by the lipoaspirate preparation, 
by helping to support the load upon the injured articular 
heads, could provide a protective action on resident chon-
drocytes, which being less stressed would be stimulated 
to regenerate, leading to repair of the damaged tissue.
In conclusion, intra-articular injection of lipoaspirate 
may be considered a possible strategy to resolve lesions 
Figure 6. Lentiviral GFP transduction of the clusters (A). No GFP-positive cells growing out from GFP-transduced clusters are vis-
ible upon a healthy cartilage fragment (B). A mechanically damaged cartilage fragment was well repopulated (C). Few of the cells 
that repopulated the damaged cartilage differentiated into chondrocytes (GFP positive and SOX-9 positive, yellow highlighted with 
arrows) (D).
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to the cartilage and osteoarthritis. This possibility shows 
promise for the production of a new generation of active 
injectable scaffolds (made of autologous tissue requiring 
no preparation steps), which could help clinicians to treat 
focal cartilage defects, osteochondral defects, and osteoar-
thritis, using lipoaspirate from the patient to be treated. The 
use of human materials for transplantation (cells, tissues, 
and organs) is not without risks that may be related to the 
donor, the process of relocating the tissue from donor to the 
patient, or the condition of the receiver. In the application 
proposed in this study, since lipoaspirate was autologous, 
there would be no risk of rejection, or of transmitting dis-
ease from donor to recipient; further, there would be no 
need for procurement, processing, testing, storage, or qual-
ity control. Some limitations must be overcome before this 
procedure could enter widespread use, such as short- and 
long-term unpredictability, in vivo intra-articular perfor-
mance, and the fate of cells outgrown from lipoaspirate 
and of the lipoaspirate itself (biodistribution).
Lipoaspirate and Lipogems® are both minimally 
manipulated autologous materials, not combined with 
other products, and intended for homologous use; they 
are therefore classified as HCT/Ps in section 361 of the 
Public Health Service Act and FDA approved for clini-
cal trials. For these reasons, the therapeutic approach is 
possible, but only clinical results will demonstrate its 
safety (ruling out inflammatory reactions, fibrosis, mal-
differentiation, and any tumorigenic activity), and further 
studies are needed to demonstrate its efficacy that might 
be dependent on age, BMI, gender, ethnicity, existing dis-
eases, or other factors.
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